Updated on 8 January 2015
Johnson & Johnson announced that Janssen has produced more than 400,000 regimens of the prime-boost vaccine for use in large-scale clinical trials by April 2015
Singapore: The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Pediatrics.
Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.
Johnson & Johnson also announced that Janssen, in partnership with Bavarian Nordic A/S, has produced more than 400,000 regimens of the prime-boost vaccine for use in large-scale clinical trials by April 2015.
A total of 2 million regimens will be available through the course of 2015, with the ability to quickly scale up to 5 million regimens, if required, over a 12- to 18-month period.
This increased projection is an update to Janssen's previous goal of producing more than 1 million regimens by the end of 2015, with 250,000 regimens for broad application in clinical trials by May 2015."As a leader in the field of global health, we have a responsibility to act swiftly as Ebola continues to cause suffering among patients, families and health care workers in West Africa," said Mr Alex Gorsky, chairman & CEO, Johnson & Johnson.